Abbott and Merck have entered a collaboration to evaluate the use of a FISH (fluorescence in situ hybridization)-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy. Abbott’s FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help determine which patients are more or less likely to benefit from a particular therapy.   Abbott will develop a test based on its FISH technology to identify deletions of the TP53 gene...